|
Market Closed -
Nasdaq
16:00:00 2026-11-02 EST
|
5-day change | 1st Jan Change | ||
| 596.13 USD | -0.43% |
|
+0.55% | +22.35% |
| 11-02 | United Therapeutics Insider Sold Shares Worth $5,700,856, According to a Recent SEC Filing | MT |
| 10-30 | United Therapeutics Insider Sold Shares Worth $5,650,415, According to a Recent SEC Filing | MT |
| Market Cap | 25.57B 22.83B 20.95B 19.06B 35.73B 2,421B 36.44B 250B 101B 1,278B 95.96B 93.92B 4,035B | P/E 2026 * |
22.4x | P/E 2027 * | 19.1x |
|---|---|---|---|---|---|
| Enterprise Value | 22.62B 20.19B 18.53B 16.86B 31.6B 2,141B 32.23B 221B 89.22B 1,130B 84.89B 83.08B 3,570B | EV / Sales 2026 * |
7.12x | EV / Sales 2027 * | 5.92x |
| Free-Float |
53.72% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| UTHR | Delayed | |
CBOE
| UTHR | Real-time | |
|
Xetra
| UTH | Delayed | |
|
Tradegate
| UTH | Real-time | |
|
Boerse Muenchen
| UTH | Real-time | |
|
Deutsche Boerse AG
| UTH | Delayed | |
|
Börse Stuttgart
| UTH | Delayed | |
|
Berne S.E.
| UTH | End-of-day quote |
Last Transcript: United Therapeutics Corporation
| 1 day | -0.43% | ||
| 1 week | +0.55% | ||
| Current month | -0.43% | ||
| 1 month | +10.05% | ||
| 3 months | +15.15% | ||
| 6 months | +4.51% | ||
| Current year | +22.35% |
| 1 week | 581.88 |  | 609.99 |
| 1 month | 523.95 | | 609.99 |
| Current year | 455.63 | | 609.99 |
| 1 year | 430.02 | | 609.99 |
| 3 years | 208.62 | | 609.99 |
| 5 years | 158.38 | | 609.99 |
| 10 years | 74.31 | | 609.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 71 | 1996-06-25 | |
| President | 54 | 2016-06-25 | |
James Edgemond
DFI | Director of Finance/CFO | 58 | 2015-03-12 |
| Director | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 78 | 2001-12-31 |
| Chairman | 71 | 1996-06-25 | |
Louis Sullivan
BRD | Director/Board Member | 92 | 2001-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/15/26 | Exercice | Chief Executive Officer | 28,500 | 0.0664% | ||
| 10/15/26 | Exercice | General Counsel | 24,900 | 0.0581% | ||
| 10/14/26 | Exercice | Chief Executive Officer | 28,500 | 0.0664% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.43% | +0.55% | +33.83% | +161.25% | 25.68B | |
| -0.46% | +10.31% | +63.52% | +143.15% | 1,263B | |
| -0.97% | +1.60% | +43.25% | +80.09% | 658B | |
| -2.05% | +0.73% | +32.47% | +101.62% | 521B | |
| -1.54% | +0.18% | +53.42% | +66.79% | 391B | |
| -0.78% | +5.51% | +72.55% | +44.25% | 369B | |
| -1.69% | +3.17% | +32.49% | +55.35% | 307B | |
| -0.72% | +7.83% | +11.15% | +33.76% | 290B | |
| -0.12% | +4.68% | +55.97% | +74.59% | 252B | |
| -0.21% | +7.34% | +42.19% | +109.69% | 212B | |
| Average | -0.83% | +4.63% | +44.08% | +87.05% | 428.76B | |
| Weighted average by Cap. | -0.73% | +5.63% | +49.06% | +93.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.18B 2.84B 2.6B 2.37B 4.44B 301B 4.53B 31.1B 12.54B 159B 11.93B 11.67B 502B | 3.6B 3.22B 2.95B 2.69B 5.04B 341B 5.14B 35.28B 14.22B 180B 13.53B 13.24B 569B |
| Net income | 1.22B 1.09B 997M 907M 1.7B 115B 1.73B 11.9B 4.8B 60.79B 4.57B 4.47B 192B | 1.41B 1.26B 1.16B 1.05B 1.97B 134B 2.01B 13.81B 5.57B 70.51B 5.3B 5.18B 223B |
| Net Debt | -2.95B -2.63B -2.42B -2.2B -4.12B -279B -4.2B -28.87B -11.64B -147B -11.07B -10.84B -466B | -4.23B -3.78B -3.46B -3.15B -5.91B -400B -6.03B -41.39B -16.68B -211B -15.87B -15.53B -668B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-02 | US$596.13 | -0.43% | 419,866 |
| 26-10-30 | US$598.72 | +0.87% | 518,240 |
| 26-10-29 | US$593.54 | +1.20% | 370,341 |
| 26-10-28 | US$586.48 | -0.80% | 421,674 |
| 26-10-27 | US$591.20 | -0.28% | 457,446 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UTHR Stock
Select your edition
All financial news and data tailored to specific country editions
